Skip to main content
. Author manuscript; available in PMC: 2024 Aug 15.
Published in final edited form as: Neuropharmacology. 2023 Apr 25;234:109545. doi: 10.1016/j.neuropharm.2023.109545

Figure 5. Inhibition of β and α1 ARs in mPFC did not affect AOD or CLAD.

Figure 5.

Intra-mPFC injection of propranolol 0.5 or 5μg (A), propranolol 10μg or betaxolol 307ng (B), or prazosin 0.3μg (C), had no impact on AOD or CLAD.